Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated August 08, 2025, titled, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the unaudited (standalone and consolidated) financial results of the Company for quarter and three months ended 30 June 2025.".
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.9 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Suraksha Diagnostic reported Q1 FY26 total income of ₹734.92 million, up 18.83% year-on-year, with revenue from operations rising 19.52% to ₹725.86 million. EBITDA grew 13.51% YoY to ₹246.56 million, though EBITDA margin compressed by 180 basis points to 33.97% (from 35.77% a year ago), reflecting cost pressure even as the topline expanded. Profit after tax increased 19.67% to ₹91.75 million with a stable PAT margin of 12.64%. The company also launched a new Suraksha Genomics vertical, acquired a 63% stake in Fetomat Wellness (pregnancy/prenatal care), and added three new diagnostic centres in the quarter.
Strong top-line and profit growth signal healthy demand for the East India diagnostic chain, but the YoY EBITDA margin slip is a watchpoint for investors. New genomics vertical and Fetomat acquisition could support medium-term growth but may also pressure margins in the near term.